Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

U.S. to widen COVID antiviral pill distribution

Published 04/26/2022, 05:09 AM
Updated 04/26/2022, 07:50 PM
© Reuters. FILE PHOTO: Pfizer's coronavirus disease (COVID-19) pill Paxlovid is packaged in Ascoli, Italy, in this undated image obtained by Reuters on November 16, 2021. Pfizer/Handout via REUTERS

By Ahmed Aboulenein

WASHINGTON (Reuters) -U.S. President Joe Biden's administration is aiming to expand access to COVID-19 oral antiviral treatments like Pfizer Inc (NYSE:PFE)'s Paxlovid by doubling the number of locations at which they are available, the White House said on Tuesday.

Pharmacies participating in the federal pharmacy program for distributing antiviral treatments will be able to order the free treatments directly from the U.S. government starting this week.

Currently, pharmacies depend on states to obtain the pills. The government sends the treatments to select pharmacies, as well as directly to states and community centers. Under the current system, the treatments are available in around 20,000 locations.

The administration expects to boost their direct distribution to more than 30,000 locations soon and reach 40,000 sites over the coming weeks, the White House said.

"Treatments are really the next phase of this pandemic, where we have to make the treatments, these highly effective treatments, widely available," Dr. Ashish Jha, the White House COVID-19 response coordinator, said in an interview on CNN.

Demand for Paxlovid has been unexpectedly light due to complicated eligibility requirements, reduced COVID testing, and potential for drug interactions.

Paxlovid was expected to be a major tool in the fight against COVID after it reduced hospitalizations or deaths in high-risk patients by around 90% in a clinical trial.

There are only a few proven antiviral treatments. The others are Merck & Co's far less effective rival pill molnupiravir, and Gilead Sciences Inc (NASDAQ:GILD)'s intravenous remdesivir.

The United States has agreed to buy up to 20 million pills at around $530 a course and Pfizer is on pace to produce 3.5 million courses earmarked for U.S. use by the end of April.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Through the first half of April, U.S. data shows it has distributed around 1.5 million courses and that pharmacies still have over 500,000 available.

The government also plans to roll out more federally supported test sites as part of its "Test to Treat" initiative that allows Americans to get tested for COVID-19 at a pharmacy and receive free pills if they test positive.

There are currently 2,200 such sites and the White House expects an additional 10,000 to come online right away.

The administration also aims to boost patient and provider awareness through public education campaigns.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.